Use of gadolinium-based contrast agents and MRI protocols: SFNR Guidelines - Page 2

Written By : Medha Baranwal |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2021-01-22T18:00:51+05:30 | Updated On 23 Jan 2021 12:19 PM IST

For cerebral venous thrombosis, GBCA is systematic with the standard dose. Phase-contrast MR-venography can be an alternative in patients with strong contra-indication for GBCAs or refusing injections (pregnancy, lactation, other).
In patients with multiple sclerosis, GBCA administration is recommended in the following situations: (A) at the time of diagnosis to evaluate diagnostic criteria and highlight the temporal dissemination; (B) if a previous MRI is not available to assess lesion burden progression; (C) when a new treatment is started and six months thereafter; (D) in case of a clinical or FLAIR relapse; and (E) when progressive multifocal leukoencephalopathy (PML) is suspected.
In patients with multiple sclerosis, GBCA injection is not recommended in the absence of imaging, clinical, or treatment modification.
In patients with chronic headache, GBCA administration is not recommended, except when other sequences show evidence of a pathological process requiring contrast-enhanced characterization.
In patients with intracranial infection, GBCA injection is recommended to search for parenchymal and meningeal enhancement, brain injury, and related complications.
For patients with intra-axial tumors, GBCAs are systematic for the diagnosis, as well as during follow-up under or after treatment.
GBCA injection is systematic for the screening for meningioma under or after treatment with cyproterone acetate.
GBCA injection is systematic for the initial diagnosis of extra-axial tumors, but can be waived on a case-by-case basis for stable benign processes.
GBCA injection is systematic for the postoperative assessment of extra-axial tumors.
GBCAs injection is systematic for the initial workup of vestibular schwannomas.
GBCA injection can be waived in patients with stable followed-up or treated schwannoma, evaluated with high-resolution T2-W sequences.
The diagnosis of pituitary microadenoma requires GBCA injection.
A non-operated macroadenoma may be followed with unenhanced sequences.

"Consensus Guidelines of the French Society of Neuroradiology (SFNR) on the use of Gadolinium-Based Contrast agents (GBCAs) and related MRI protocols in Neuroradiology," is published in the Journal of Neuroradiology.

DOI: https://www.sciencedirect.com/science/article/pii/S0150986120301978

Journal of NeuroradiologyFrench Society of Neuroradiologygadolinium-based contrast agentsMRI

Source : Journal of Neuroradiology

Medha Baranwal

MSc. Biotechnology

Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751